共 50 条
- [41] First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind studyEUROPEAN JOURNAL OF CANCER, 2012, 48 (04) : 547 - 563Demetri, George D.Le Cesne, AxelChawla, Sant P.Brodowicz, ThomasMaki, Robert G.Bach, Bruce A.Smethurst, Dominic P.Bray, SarahHei, Yong-jiangBlay, Jean-Yves
- [42] Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label StudyCANCERS, 2023, 15 (10)Kadono, YoshifumiKonaka, HiroyukiNohara, TakahiroIzumi, KoujiAnai, SatoshiFujimoto, KiyohideKoguchi, TomoyukiIshibashi, KeiKawai, NoriyasuNakane, KeitaIba, AkinoriMasumori, NaoyaTakahara, ShizukoMizokami, Atsushi
- [43] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyLANCET, 2023, 402 (10408): : 1133 - 1146Qin, ShukuiChan, Stephen L.Gu, ShanzhiBai, YuxianRen, ZhenggangLin, XiaoyanChen, ZhendongJia, WeidongJin, YongdongGuo, YabingHu, XiaohuaMeng, ZhiqiangLiang, JunCheng, YingXiong, JianpingRen, HongYang, FangLi, WeiChen, YajinZeng, YongSultanbaev, AlexanderPazgan-Simon, MonikaPisetska, MargarytaMelisi, DavidePonomarenko, DmitriyOsypchuk, YuriiSinielnikov, IvanYang, Tsai-ShengLiang, XiaoChen, ChunxiaWang, LinnaCheng, Ann-LiiKaseb, AhmedVogel, Arndt
- [44] A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinomaANNALS OF ONCOLOGY, 2005, 16 : 41 - 41Grimm, MOMachiels, JPWülfing, CRichel, DTreiber, Ude Groot, MBeuzeboc, PFarrell, JColman, JEl-Hariry, I
- [45] MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 221Smith, I. E.Biganzoli, L.Cortes-Funes, H.Franke, F.Kamel, Y. MostafaPierga, J. Y.Pritchard, K. I.Stroyakovs, D.Thomssen, C.Vinholes, J.
- [46] Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trialLANCET ONCOLOGY, 2014, 15 (11): : 1269 - 1278von Minckwitz, GunterPuglisi, FabioCortes, JavierVrdoljak, EduardMarschner, NorbertZielinski, ChristophVillanueva, CristianRomieu, GillesLang, IstvanCiruelos, EvaDe laurentiis, MicheleVeyret, Corinnede Ducla, SabineFreudensprung, UlrichSrock, StefanieGligorov, Joseph
- [47] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 343S - 343SSong, HSDo, YRChang, HMLee, KHKim, YHHong, DSCho, JYLee, KEKim, SYRyu, MH
- [48] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II studyBMC CANCER, 2024, 24 (01)Cheng, YuTeng, ZanZhang, YanqiaoJin, BoZheng, ZhendongMan, LiWang, ZhenghuaTeng, YueeYu, PingShi, JingLuo, YingWang, YingZhang, JingdongZhang, HuijuanLiu, JiweiChen, HaoXiao, JiawenZhao, LeiZhang, LingyunJiang, YuChen, YingZhang, JianWang, ChangLiu, SaQu, JingleiQu, XiujuanLiu, Yunpeng
- [49] First-line Treatment for advanced Renal Cell Carcinoma A Phase 3, open-label, randomized Study of Atezolizumab (Anti-PD-L1-Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with untreated advanced Renal Cell Carcinoma ("IMmotion") AN 37/15 of AUOUROLOGE, 2016, 55 (09): : 1242 - 1243Rexer, H.Doehn, C.
- [50] KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Doi, ToshihikoBennouna, JaafarShen, LinEnzinger, Peter C.Wang, RuixueCsiki, IldikoKoshiji, MinoriShah, Manish A.